H.T. Mouridsen

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

Carsten Rose, K W Andersen, H.T. Mouridsen et al. · The Lancet · 1985 · 209 citations

Medicine, Endocrinology, Oncology +8

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

A.T. van Oosterom, H.T. Mouridsen, Ole S. Nielsen et al. · European Journal of Cancer · 2002 · 164 citations

Medicine, Oncology, Pharmacology +13

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

OS Nielsen, P Dombernowsky, H.T. Mouridsen et al. · British Journal of Cancer · 1998 · 110 citations · Full text

Medicine, Oncology, Pharmacology +11

A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results

M Blichert-Toft, H Brincker, J. A. Andersen et al. · Acta Oncologica · 1988 · 93 citations · Full text

Medicine, Oncology, Surgery +9

Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.

H Brincker, Carsten Rose, Fritz Rank et al. · Journal of Clinical Oncology · 1987 · 92 citations

Medicine, Oncology, Pharmacotherapy +16